Genetic studies have linked the VTI1A-TCF7L2 region with risk of multiple cancers. However, findings from these studies were generally inconclusive. We aimed to provide a synopsis of current understanding of associations between variants in the VTI1A-TCF7L2 region and cancer susceptibility. We conducted a comprehensive research synopsis and meta-analysis to evaluate associations between 17 variants in this region and risk of seven cancers using data from 32 eligible articles totaling 224,656 cancer cases and 324,845 controls. We graded cumulative evidence of significant associations using Venice criteria and false-positive report probability tests. We also conducted analyses to evaluate potential function of these variants using data from the Encyclopedia of DNA Elements (ENCODE) Project. Eight variants showed a nominally significant association with risk of individual cancer (p < 0.05). Cumulative epidemiological evidence of an association was graded as strong for rs7903146 [odds ratio (OR) 5 1.05, p 5 4.13 3 10 25
genome-wide association studies (GWAS) and large-scale collaborative studies have identified hundreds of singlenucleotide polymorphisms (SNPs) associated with susceptibility to human cancers. 3 Both VTI1A (Gene ID: 143187) and TCF7L2 (Gene ID: 6934) are located at chromosome 10q25.2. The TCF7L2 gene product is a high mobility group box-containing transcription factor that plays a key role in the Wnt signaling pathway 4 while the VTI1A gene encodes a soluble N-ethylmaleimidesensitive fusion protein-attachment protein receptor that functions in intracellular trafficking. 5 Over the past decade, genetic association studies have linked common variants in the TCF7L2 gene with risk of multiple cancers. Initially, the TCF7L2 gene was identified as a susceptibility locus for type 2 diabetes in populations of European ancestry in 2006. 6 Based on an epidemiological link between type 2 diabetes and cancer, 7 a number of candidate-gene association studies have been conducted to investigate the potential associations between rs7903146 and rs12255372 in intron 3 of the TCF7L2 gene and risk of colorectal cancer, 8 breast cancer, 9 prostate cancer, 10 ovarian cancer 11 and hepatocellular carcinoma. 12 In 2013, a large-scale collaborative effort conducted in populations of European ancestry involving 55,342 cases and 54,455 controls identified rs7904519 in intron 4 of the TCF7L2 gene as a susceptibility locus for breast cancer 13 and the SNP was subsequently confirmed to be associated with an increased risk of triple-negative breast cancer. 14 Recently, a GWAS done in East Asians with 14,963 cases and 31,945 controls identified rs11196172 in intron 4 of the TCF7L2 gene associated with colorectal cancer risk 15 and this association was further evaluated in Europeans, 16 Chinese 17 and Hispanics. 18 Since 2012, genetic studies have also been conducted to evaluate associations between common variants in the VTI1A gene and risk of human cancers. A GWAS performed in Asian women who never smoked identified a susceptibility locus for lung cancer represented by rs7086803, which maps to intron 7 of the VTI1A gene 19 and association of this SNP with lung cancer was also evaluated in a Chinese population. 20 GWAS performed in populations of European ancestry identified rs11196067 in intron 7 of the VTI1A gene associated with risk of glioma 21 and this association was further evaluated in two additional studies. 22, 23 In addition, two variants, rs12241008 and rs10506868 located in intron 3 and intron 6 of the VTI1A gene, respectively, were found to be associated with risk of colorectal cancer. [16] [17] [18] 24, 25 Although a bundle of genetic studies have been done to evaluate the contribution of variants in the VTI1A-TCF7L2 region to risk of human cancers thus far, findings from these studies were generally inconsistent and the mechanisms of these associations remain unclear. Several preliminary metaanalyses focused on evaluating association between a single SNP (rs12255372 or rs7903146) in the TCF7L2 gene and risk of an individual cancer, [26] [27] [28] [29] and conclusions have been inconclusive due to limited data derived from a small sample size. Furthermore, these meta-analyses did not perform a systematic functional annotation for these variants. In this study, we attempted to evaluate all genetic studies that investigated associations between variants in the VTI1A and TCF7L2 genes and risk of human cancers, perform meta-analyses for variants with sufficient data available, summarize cumulative epidemiological evidence for variants with significant association, perform a systematic functional annotation and provide a synopsis of our current understanding of the relationships between variants in the VTI1A-TCF7L2 region and cancer susceptibility.
Methods
All methods were based on guidelines proposed by the Human Genome Epidemiology Network for systematic review of genetic association studies 30 and followed the guidelines of Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). 31 
Search strategy and selection criteria
We systematically searched PubMed and Embase to identify genetic association studies (cross-sectional studies, casecontrol studies, cohort studies, or GWAS) published in print or online before April 30th, 2017 in English language using key terms "TCF7L2 or transcription factor 7-like 2 or TCF-4 or VTI1A or vesicle transport through interaction with tSNAREs 1 A" and "variant or variation or polymorphism or genotype" and "cancer or carcinoma or tumor". We also screened the references of all included studies, reviews, metaanalyses and related citations in PubMed to identify additional publications. The eligibility of each study was assessed independently by two investigators (M.Z. and Y.F.). The articles included in the meta-analysis must meet the following inclusion criteria: (i) evaluating the associations of genetic variants in the VTI1A-TCF7L2 region with risk of human cancer; (ii) providing age-adjusted or multivariate-adjusted risk estimates [e.g., relative risks, hazard ratios, odds ratios (ORs), regression coefficients, 95% confidence intervals (CIs) or standard errors] or sufficient data to calculate these estimates. If the same study population was reported in more than one articles, we included data from the most recent or the largest publication. Studies were excluded when: (i) they lacked sufficient information; (ii) the sample size was <200; (iii) they were not published as full reports, such as conference abstracts and letters to editors; (iv) they were studies of cancer mortality (rather than incidence); (v) they were studies of cancer precursors (e.g., colorectal adenoma).
Data extraction, preparation and management
Data were extracted by one investigator (M.Z.) and subsequently checked by two others (Y.F. and S.C.). Data extracted from each eligible publication included first author, publishing year, PubMed identifier number, study design, method of case selection, source population, ethnicity of participants, mean ages of cases and controls, sample size, cancer type, genes, variants, major and minor alleles, genotype counts for cases and controls, Hardy-Weinberg equilibrium (HWE) among controls and genotyping methods used. Specifically, case selection was classified as population-based, hospital-based, or mixed. Ethnicity was classified as African (African descent), Asian (East Asian descent), Caucasian (European descent) or other (including Native Hawaiians, Latinos, Hispanics, etc.) based on the ethnicity of at least 80% of the study population. In total, 32 eligible publications had sufficient data available for extraction and inclusion in meta-analyses.
Statistical analysis and assessment of cumulative evidence
All statistical tests in this study were two-tailed and p values of <0.05 were considered significant unless otherwise stated. Statistical analysis was performed with Stata, version 13 (Stata, College Station, TX). We combined the ORs of variants in VTI1A-TCF7L2 region with cancer risk from each of the included studies using a random-effects inverse-variance weighted meta-analysis to obtain summary results of associations. To keep results consistent with the original ones, we adopted the method used in initial studies if data were obtained from GWAS or large GWAS meta-analysis from collaborative studies. For studies reporting only categorical results, the ORs of variants in VTI1A-TCF7L2 region associated with cancer were calculated using the generalized least squares method, assuming linearity of the natural log-scale ORs. In our study, we conducted meta-analysis using additive genetic model. Effects associated with minor alleles were evaluated for each of the variants. Because major and minor alleles can be reversed in populations of different ethnicities, averaged minor allele frequency (MAF) across studies may be >50%. When this occurred, the minor allele among Caucasians was used as the minor allele in all analyses. For studies reporting multiple models, the most fully adjusted OR was collected. For publications that contained multiple studies (datasets), individual result for each of these studies was used in our meta-analysis.
We performed Cochran's Q test 32 35 An excess of significant findings was evaluated using the method described by Ioannidis and Trikalinos. 36 In
Cochran's Q, Begg's and Egger's tests, as well as test for excess significant findings, p values of <0.10 was considered significant as recommended. [32] [33] [34] [35] [36] We applied the Venice criteria 37 to evaluate the epidemiological credibility of significant associations identified by meta-analysis (see Supporting Information notes). Briefly, credibility was defined as strong, moderate, or weak, based on the grade of A, B or C in three categories: amount of evidence, replication of the association and protection from bias. Amount of evidence was graded by the sum of test alleles or genotypes among cases and controls: A for > 1,000, B for 100-1,000 and C for < 100. Replication was graded by the heterogeneity statistic: A for I 2 < 25%, B for I 2 between 25 and 50%, and C for I 2 > 50%. For replication of the association, qualitative epidemiologic considerations about the presence of heterogeneity and potential explanation for heterogeneity would need to be taken into account in judging replication. 38 It may be reasonable to grade as A on this criterion for associations with moderate or high heterogeneity with an extensive replication record such as associations identified by GWAS or large GWAS meta-analysis from collaborative studies. 38 Protection from bias was mainly determined by sensitivity analysis and a series of bias tests including publication bias, small-study bias, as well as an excess of significant findings. Briefly, protection from bias was graded as A if there was no observable bias, and bias was unlikely to explain the presence of the association, B if bias could be present, or C if bias was evident or was likely to explain the presence of the association. The Venice criteria included an extensive checklist for sources of bias in different settings (see Supporting Information notes). Assessment of protection from bias also considered the magnitude of association; a score of C was assigned to an association with a summary OR <1.15, unless the association had been replicated prospectively by several studies with no evidence of publication bias (i.e., GWAS or GWAS meta-analysis from collaborative studies). 38 Therefore, the cumulative epidemiological evidence for significant associations was thought to be
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strong if all three grades were A, moderate if all three grades were A or B and weak if any grade was C. False positive report probability (FPRP) was estimated to determine whether a significant association could be excluded as a false positive finding. We used the method described by Wacholder et al. 39 to calculate FPRP at prior probability of 0.05 for the significant associations and adopted an FPRP cut-off value of 0.20. FPRP < 0.05, 0.05 FPRP 0.20 and FPRP > 0.20 were considered strong, moderate and weak evidence of true association, respectively. If evidence of a true association based on the FPRP analysis was strong, we upgraded cumulative evidence from weak to moderate and from moderate to strong. If evidence of a true association was weak, we downgraded cumulative evidence from moderate to weak and from strong to moderate. Statistical power and the FPRP value were computed using the Excel spreadsheet provided by Wacholder et al.
Functional annotation
We conducted analyses to evaluate the potential functional effect of variants on 10q25.2 using data from the Encyclopedia of DNA Elements (ENCODE) Project and performed functional annotation for variants significantly associated with cancer risk through the UCSC Genome browser (http:// genome.ucsc.edu/).
Results

Characteristics of the studies included in this metaanalysis
Our search yielded a total of 301 publications ( Fig. 1 ). Sixtyfive duplicate publications and 190 irrelevant publications were excluded after title or abstract review. Four metaanalyses, two publications with insufficient data, one publication with sample size <200 and additional seven irrelevant publications were further excluded on the basis of full text review. Thus, 32 articles (Supporting Information references) containing 276 datasets for associations between 17 variants in VTI1A-TCF7L2 region and cancer risk were eligible to be included in our meta-analysis. Characteristics of the included articles were presented in Table 1 . Of the 276 datasets, 144 were on breast cancer, 93 were on colorectal cancer, 17 were on lung cancer, 11 were on glioma, seven were on prostate cancer, three were on hepatocellular carcinoma and one was on ovarian cancer. All the 32 articles were published after 2005, with three fourths published since 2010 (n 5 24). In total, we analyzed data from a total of 224,656 cancer cases and 324,845 controls. Meta-analyses of an association with the five cancers were done for eight variants in VTI1A-TCF7L2 region.
Associations between VTI1A-TCF7L2 variants and cancer risk A summary of the meta-analysis findings regarding associations between variants in VTI1A-TCF7L2 region and cancer risk under an additive genetic model was shown in Table 2 Cancer Epidemiology Cancer Epidemiology ). In addition, data for rs10506868 was only available in Asians and association of this SNP with risk of colorectal cancer needs to be further evaluated in other ethnic groups.
Significant association with risk of lung cancer was found for rs7086803 (OR 5 1.30, 95% CI: 1.23-1.37; p 5 3.54 3 10
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) but not for rs7903146 (OR 5 1.13, 95% CI: 0.67-1.91; p 5 0.645) in Asians (Table 2) . Meanwhile, rs11196067 was observed to be significantly associated with risk of glioma (OR 5 1.18, 95% CI: 1.13-1.23; p 5 3.59 3 10
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; Table 2 ). In addition, we observed a significant association between rs290489 and increased risk of hepatocellular carcinoma (OR 5 1.31, 95% CI: 1.08-1.60; p 5 0.007) in one article (Table 1) . Nevertheless, associations of variants with risk of prostate cancer and ovarian cancer were not significant in combined analysis of all studies and subgroup analysis.
Heterogeneity, sensitivity analysis and bias
As shown in Table 2 59.0%, p 5 0.009) with glioma, however, was large. We performed sensitivity analysis to evaluate the stability of results of these associations and found that removal of a single study (dataset), the first published or first positive report or studies deviated from HWE in controls did not change the summary ORs (data not shown). There was little evidence of bias for associations between variants and risk of breast cancer, colorectal cancer, prostate cancer and lung cancer in combined analysis of all studies or subgroup analysis by ethnicity (p > 0.10 for all tests) with the exception of a small-study bias found for rs7903146 associated with colorectal cancer (p 5 0.055). We were unable to conduct sensitivity analyses and examine bias for associations between other variants in this region and cancer risk due to insufficient data. We did not evaluate the excess of significant findings because genotype counts from most studies were unavailable.
Cumulative evidence of association
Epidemiological credibility was graded for the nine significant associations identified through the main analyses (Table 2) . We first applied Venice criteria to evaluate these associations. Details of protection from bias for genetic variants significantly associated with cancer risk in meta-analyses is shown in Supporting Information Table S1 . Grades of A were given to nine, eight and seven meta-analyses for amount of Datasets represented the number of datasets in the original publications.
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evidence, replication of association and protection from bias, respectively. Grades of B were given to zero, one and zero meta-analyses for amount of evidence, replication of association and protection from bias, respectively. Grades of C were given to zero, zero and two meta-analyses for these three criteria, respectively. Thus, strong, moderate and weak for evidence of true association with cancer risk were assigned to seven (rs7903146 and rs7904519 in breast cancer, rs11196172, rs12241008 and rs10506868 in colorectal cancer, rs7086803 in lung cancer, rs11196067 in glioma), zero and two variants (rs12255372 in breast cancer, rs7903146 in colorectal cancer), respectively. Next, we evaluated the probability of true association with cancer risk for the nominally significant variants through calculating the FPRP value. Associations with cancer risk had a FPRP value < 0.05 for eight variants (rs12255372, rs7903146, rs7904519 in breast cancer, rs11196172, rs12241008 and rs10506868 in colorectal cancer, rs7086803 in lung cancer, rs11196067 in glioma), FPRP value 0.05-0.20 for one variant (rs7903146 in colorectal cancer) and none of the associations had a FPRP value > 0.20. For rs12255372 associated with breast cancer, we upgraded cumulative evidence from weak to moderate based on a FPRP value of 0.005. Altogether, cumulative epidemiological evidence of an association was graded as strong for rs7903146 and rs7904519 in breast cancer, rs11196172, rs12241008 and rs10506868 in colorectal cancer, rs7086803 in lung cancer and rs11196067 in glioma, moderate for rs12255372 in breast cancer and weak for rs7903146 in colorectal cancer.
Functional annotation
Data from the ENCODE Project suggested that variants rs7903146, rs11196172, rs7904519, rs12241008, rs10506868, rs11196067 and rs7086803, as well as other correlated variants might be located in a region with strong enhancer activity and DNase I hypersensitivity site. The linkage disequilibrium (LD) plots indicated that the genetic structure of regions represented by these variants is different in populations of European, Asian and African ancestry (Fig. 4) .
Discussion
To our knowledge, this study is the largest and most comprehensive assessment of literatures on associations between genetic variants in the VTI1A-TCF7L2 region and cancer risk done thus far. Several meta-analyses have been conducted to evaluate candidate-gene association studies of cancer risk for variants in the TCF7L2 gene. [26] [27] [28] [29] These preliminary analyses, however, were mostly limited to a single SNP in relation to one cancer, with 14,814 cases and 33,856 controls in the largest study. 27 Following guidelines proposed by the Human Genome Epidemiology Network, 30 we performed a research synopsis and meta-analysis to systematically evaluate associations between 17 variants in this region and risk of seven human cancers using data from 32 articles including a total of 224,656 cancer cases and 324,845 controls. Our study not 
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Note: A, adenine; C, cytosine; G, guanine; T, thymine; OR, odds ratio; CI, confidence interval; MAF, minor allele frequency in control; NA, not applicable; FPRP, false positive report probability.
1 Alleles: Minor allele (bold) versus major allele. Venice criteria grades are for amount of evidence, replication of the association and protection from bias. 3 The prior probability of FPRP is 0.05, and the FPRP level of noteworthiness is 0.20.
Cancer Epidemiology only provides an update of the variants analyzed previously using data from more studies and a bigger sample size, but also evaluates more variants that have not been analyzed in previous meta-analyses. Of the variants evaluated in the 11 main meta-analyses, eight were significantly associated with risk of breast cancer, colorectal cancer, lung cancer and glioma, including a variant associated with both breast cancer and colorectal cancer. Using the Venice criteria and falsepositive report probability tests, we graded seven variants (rs7903146 and rs7904519 in breast cancer, rs11196172, rs12241008 and rs10506868 in colorectal cancer, rs7086803 in lung cancer and rs11196067 in glioma) strong for cumulative evidence of significant associations with cancer risk. Furthermore, we performed functional annotation for variants significantly associated with cancer risk using data from the ENCODE Project and the UCSC Genome browser and found that these variants might be located in a region with strong enhancer activity and DNase I hypersensitivity site. Overall, our study provides summary evidence that common variants in the VTI1A-TCF7L2 region are associated with risk of breast cancer, colorectal cancer, lung cancer and glioma. The TCF7L2 gene (Gene ID: 6934) encodes a high mobility group box-containing transcription factor TCF7L2 (formerly known as TCF4) that plays a key role in the Wnt signaling pathway. Aberrant activation of Wnt signaling is found in >90% of colorectal cancer. 40 Loss of TCF7L2 function enhances colorectal cancer cell growth, 41 whereas gain of function suppresses colorectal cancer cell growth. 42 The TCF7L2 gene is one of the most frequently mutated genes in colorectal cancer, with an estimated point mutation rate of 10%. 40 In this study, cumulative evidence of an association with cancer risk was graded as strong for three variants (rs7903146, rs7904519 and rs11196172) in the TCF7L2 gene. Of the two variants associated with breast cancer, rs7903146 and rs7904519, respectively, are located in intron 3 and intron 4 of the TCF7L2 gene. Using data from Phase 3 of the 1000 Genomes Project, 43 we found that rs7903146 is in moderate LD with rs7904519 in Europeans (r 2 5 0.450) whereas correlation between the two variants is weak in East Asians (r 2 5 0.196) and Africans (r 2 5 0.050), consistent with the genetic structure of regions represented by them in different ethnic groups. These findings suggest that the functional mechanisms of the two variants associated with breast cancer risk may be distinct in different ethnic groups and partly explain why some variants are found to be associated with a cancer site in one ethnic group but not in others. The variant rs11196172 associated with colorectal cancer maps to intron 4 of the TCF7L2 gene and is uncorrelated with both rs7903146 and rs7904519 in Europeans, Asians and Africans (r 2 < 0.05 for all tests), reflecting that there might be different functional mechanisms for associations of TCF7L2 variants with risk of breast cancer and colorectal cancer.
The VTI1A gene (Gene ID: 143187) is located at 131 kb upstream of the TCF7L2 gene and encodes a soluble N-ethylmaleimide-sensitive fusion protein-attachment protein receptor that functions in intracellular trafficking and is involved in vesicular transport between endosomes and the trans-Golgi network. Loss of VTI1A activity has been reported to reduce high frequency spontaneous neurotransmitter release 44 and rapid progressive neurodegeneration in peripheral ganglia. 45 Recently, a recurrent gene fusion connecting the first three exons of the VTI1A gene Figure 4 . Evidence from ENCODE data for regulatory function of SNPs in 10q25.2 using the UCSC Genome Browser. The plot represent 10q25.2 within a 1,000-kb window centered on VTI1A-TCF7L2 gene region (NCBI Human Genome GRCh37). Tracks (from top to bottom) in each of the plots are Genome Base Position, Chromosome Bands, UCSC Genes, Human mRNAs from GenBank, Human ESTs That Have Been Spliced, ENCODE Enhancer-and Promoter-Associated Histone Mark (H3K4Me1) on 8 Cell Lines, ENCODE Promoter-Associated Histone Mark (H3K4Me3) on 9 Cell Lines, ENCODE Digital DNaseI Hypersensitivity Clusters, ENCODE Transcription Factor ChIP-seq, ENCODE Chromatin State Segmentation by HMM from Broad Institute (bright red, active promoter; light red, weak promoter; purple, inactive/poised promoter; orange, strong enhancer; yellow, weak/poised enhancer; blue, insulator; dark green, transcriptional transition/elongation; light green, weak transcribed; gray, polycomb-repressed; light gray, heterochromatin/low signal/repetitive/copy number variation), Simple Nucleotide Polymorphisms (dbSNP build 130), LD for the Yoruba (YRI) from Phased Genotypes, LD for the CEPH (CEU) from Phased Genotypes and LD for the Han Chinese 1 Japanese from Tokyo (CHB 1 JPT) from Phased Genotypes.
to the fourth exon of the TCF7L2 gene was found in 3% of colorectal carcinomas. 46 Our study revealed strong evidence of an association with cancer risk for four variants (rs12241008, rs10506868, rs7086803 and rs11196067) in the VTI1A gene. Of the two variants associated with colorectal cancer, rs12241008 and rs10506868, respectively, map to intron 3 and intron 6 of the VTI1A gene. The variant rs12241008 is weakly correlated with rs10506868 in Europeans (r 2 5 0.201) and moderately correlated with rs10506868 in East Asians (r 2 5 0.647) but uncorrelated with rs10506868 in Africans (r 2 5 0.014). These findings suggest that the functional mechanisms of the two variants associated with colorectal cancer risk may be distinct in different ethnic groups and further explain why some variants are found to be associated with a cancer site in one ethnic group but not in others. Both variants rs7086803 associated with lung cancer risk and rs11196067 associated with glioma risk are located in intron 7 of the VTI1A gene. Correlation between the two variants, however, is weak in European (r 2 5 0.018), East Asian (r 2 5 0.228) and African (r 2 5 0.077) populations and both of them are uncorrelated with rs12241008 and rs10506868 in European, East Asian and African populations (r 2 < 0.05 for all tests). In addition, none of the four variants in the VTI1A gene are correlated with the three variants in the TCF7L2 gene in European, East Asian and African populations (r 2 < 0.05 for all tests). These data continue to indicate that there might be different causal variants and functional mechanisms involved in associations of variants in the VTI1A and TCF7L2 genes with risk of breast cancer, colorectal cancer, lung cancer and glioma.
Data from the ENCODE project showed the seven variants with strong evidence of an association with cancer risk (rs7903146, rs7904519, rs11196172, rs12241008, rs10506868, rs7086803 and rs11196067) in the VTI1A and TCF7L2 genes and other correlated variants fall within a region with strong enhancer activity and DNase I hypersensitivity site. Using data from the Cancer Genome Atlas Project, Zhang et al. found that the risk allele of rs11196172 was significantly associated with higher expression of TCF7L2 and VTI1A in colon tumor tissue. 15 These preliminary data together suggest that these variants themselves or other variants correlated with them might be responsible for the associations with different cancers. However, the particular mechanisms how variants in the VTI1A-TCF7L2 region are related to cancer risk are yet to be elucidated. Based on findings from our study, further studies are warranted to investigate the functional mechanism of variants associated with risk of a specific cancer.
There are several limitations of the study. First, it is likely that some publications were overlooked although we conducted an exhaustive literature search. For example, key terms we used to search are not in main text but in supplementary materials of a publication. We have extended full text review to include both main text and supplementary materials of a publication. Second, we were unable to access raw data from the original publications and define a unified analysis standard across studies. To minimize the bias, we included only studies with age or multivariable-adjusted risk estimates. Third, only one study was conducted to evaluate the association of VTI1A-TCF7L2 variants with risk of ovarian cancer and hepatocellular carcinoma, respectively, and thus meta-analysis was not done for the two cancers. Fourth, we were unable to evaluate publication bias for associations between several variants in this region and cancer risk, and evaluate the excess of significant findings due to insufficient data. Finally, we conducted meta-analysis based on minor allele of a variant. Thus, some of the variants might show a protective effect. For example, rs1225404 and rs7903146 were associated with a decreased risk of breast cancer. Most of these limitations, however, are inherent in a meta-analysis. Therefore, future studies with much larger sample size are warranted to confirm or refute these associations.
In summary, we have identified seven variants in the VTI1A-TCF7L2 region that showed strong evidence of an association with cancer risk in this large-scale research synopsis and meta-analysis. Our study provides summary evidence that common variants in the VTI1A and TCF7L2 genes are associated with risk of breast cancer, colorectal cancer, lung cancer and glioma and highlights the significant role of the VTI1A-TCF7L2 region in the pathogenesis of human cancers. Further functional studies are needed to explore the exact mechanisms of VTI1A-TCF7L2 variants involved in various cancers and populations.
